|
|
Marketing Authorisations
|
|
|
|
|
First-line choice for patients at low or intermediate risk of relapse
|
|
|
|
|
|
|
|
|
|
No proven therapeutic advance at this point
|
|
|
|
|
|
|
|
|
|
May offer a greater chance of receiving a transplant, but many severe adverse effects
|
|
|
|
|
|
|
|
|
|
|
|
No proven impact on survival
|
|
|
|
|
|
|
|
|
|
No better than existing alternatives
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reviews
|
|
|
|
|
Aciclovir when an antiviral is justified
|
|
|
|
|
|
|
|
|
|
Neuroleptics should not be used
|
|
|
|
|
|
|
|
|
|
|
|
Poor documentation, adverse effects underestimated
|
|
|
|
|
|